Drug intelligence / Profile preview

ChAd155-RG

Development stage: Phase 1
Lead developer: GSK
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

ChAd155-RG is a replication-defective chimpanzee adenovirus-vectored vaccine candidate for rabies. It consists of a replication-defective group C chimpanzee adenovirus (ChAd155) expressing rabies glycoprotein (RG) under the control of the CMV promoter. The RG sequence cloned into the ChAd155 vector is a medoid, a natural viral strain. The vaccine is administered intramuscularly and is designed to induce an immune response against rabies virus.

Other names: ChAd155-RG rabies vaccineChAd-155-RG rabies vaccineChAd 155-RG rabies vaccinerabies vaccine-National Institute of Allergy and Infectious Diseases (NIAID)-rabies

Targets

RABV-G (Rabies virus glycoprotein)

Beyond the preview

Go deeper on ChAd155-RG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChAd155-RG.

Explore the full profile